These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 28182611)

  • 21. Daclatasvir: potential role in hepatitis C.
    Lee C
    Drug Des Devel Ther; 2013; 7():1223-33. PubMed ID: 24204123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens.
    Zhou N; Han Z; Hartman-Neumann S; DeGray B; Ueland J; Vellucci V; Hernandez D; McPhee F
    J Antimicrob Chemother; 2016 Dec; 71(12):3495-3505. PubMed ID: 27605597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions.
    Yu ML; Hung CH; Huang YH; Peng CY; Lin CY; Cheng PN; Chien RN; Hsu SJ; Liu CH; Huang CF; Su CW; Huang JF; Liu CJ; Kao JH; Chuang WL; Chen PJ; Chen DS
    J Formos Med Assoc; 2019 Feb; 118(2):556-564. PubMed ID: 30527566
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of genotype 1 HCV infection in the HIV coinfected patient in 2014.
    Chastain CA; Naggie S
    Curr HIV/AIDS Rep; 2013 Dec; 10(4):408-19. PubMed ID: 24272069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
    Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
    J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease.
    Mandorfer M; Schwabl P; Steiner S; Scheiner B; Chromy D; Bucsics T; Stättermayer AF; Aichelburg MC; Grabmeier-Pfistershammer K; Trauner M; Reiberger T; Peck-Radosavljevic M
    AIDS; 2016 Apr; 30(7):1039-47. PubMed ID: 26760453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA foundation cohorts.
    Rossotti R; Tavelli A; Bonora S; Cingolani A; Lo Caputo S; Saracino A; Soria A; Marinaro L; Uberti-Foppa C; Mussini C; Puoti M; d'Arminio Monforte A
    Dig Liver Dis; 2020 Apr; 52(4):447-451. PubMed ID: 31959479
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease: A retrospective study.
    Scheiner B; Schwabl P; Steiner S; Bucsics T; Chromy D; Aichelburg MC; Grabmeier-Pfistershammer K; Trauner M; Peck-Radosavljevic M; Reiberger T; Mandorfer M
    Medicine (Baltimore); 2016 Jul; 95(27):e4061. PubMed ID: 27399090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort.
    Lacombe K; Fontaine H; Dhiver C; Metivier S; Rosenthal E; Antonini T; Valantin MA; Miailhes P; Harent S; Batisse D; Pageaux GP; Chas J; Aumaitre H; Dominguez S; Allegre T; Lafeuillade A; Billaud E; De Truchis P; Perre P; Leroy V; De Ledinghen V; Sogni P; Dabis F; Zhao Y; Filipovics A; Fedchuk L; Akremi R; Bennai Y; Salmon Ceron D
    J Acquir Immune Defic Syndr; 2017 May; 75(1):97-107. PubMed ID: 28272163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Addition of ribavirin to daclatasvir plus asunaprevir for chronic hepatitis C 1b patients with baseline NS5A resistance-associated variants improved response.
    Hong CM; Liu CJ; Yeh SH; Chen PJ
    J Formos Med Assoc; 2017 Apr; 116(4):295-299. PubMed ID: 28034492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of Sofosbuvir and Daclatasvir Plasma Trough Concentrations with Patient-, Treatment-, and Disease-Related Factors Among HIV/HCV-Coinfected Persons.
    Mastrorosa I; Tempestilli M; Notari S; Lorenzini P; Fabbri G; Grilli E; Bellagamba R; Vergori A; Cicalini S; Ammassari A; Agrati C; Antinori A
    Eur J Drug Metab Pharmacokinet; 2022 Jan; 47(1):135-142. PubMed ID: 34623616
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders.
    Uemura H; Tsukada K; Mizushima D; Aoki T; Watanabe K; Kinai E; Teruya K; Gatanaga H; Kikuchi Y; Sugiyama M; Mizokami M; Oka S
    PLoS One; 2017; 12(10):e0186255. PubMed ID: 29045448
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness and security of chronic hepatitis C treatment in coinfected patients in real-world.
    Uriarte-Pinto M; Navarro-Aznarez H; De La Llama-Celis N; Arazo-Garcés P; Martínez-Sapiña AM; Abad-Sazatornil MR
    Int J Clin Pharm; 2018 Jun; 40(3):608-616. PubMed ID: 29556931
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection.
    Lv DD; Wang ML; Chen EQ; Wu DB; Tao YC; Zhang DM; Tang H
    Eur J Gastroenterol Hepatol; 2019 Mar; 31(3):382-388. PubMed ID: 30383554
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sofosbuvir-Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort.
    de Lédinghen V; Lusivika-Nzinga C; Bronowicki JP; Zoulim F; Larrey D; Metivier S; Tran A; Marcellin P; Samuel D; Chazouillères O; Chevaliez S; Dorival C; Fontaine H; Pawlotsky JM; Carrat F; Pol S;
    J Viral Hepat; 2020 Oct; 27(10):964-973. PubMed ID: 32436335
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative efficacy of sofosbuvir-ribavirin versus sofosbuvir-daclatasvir for treatment of chronic hepatitis C in an area with limited NS5A inhibitor availability.
    Kurniawan J; Gani RA; Hasan I; Sulaiman AS; Lesmana CRA; Jasirwan COM; Kalista KF; Nababan SHH; Zulkifly S
    Indian J Gastroenterol; 2018 Nov; 37(6):520-525. PubMed ID: 30637537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Role of Hepatitis C Virus NS5A Region Mutation and SNP IL-28B of Host to Support Successful Pegylated Interferon and Ribavirin Treatment in Patients with HCV-HIV Coinfection: A Prospective Cohort Study.
    Kurniawan J; Gani RA; Djauzi S; Ibrahim F; Harimurti K; Nafrialdi N; Imannuel S
    Acta Med Indones; 2019 Apr; 51(2):128-136. PubMed ID: 31383827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
    Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
    Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C.
    Yu JH; Lee JI; Lee KS; Kim JK
    Virol J; 2017 Aug; 14(1):164. PubMed ID: 28836992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective.
    Hawkins C; Grant J; Ammerman LR; Palella F; Mclaughlin M; Green R; Mcgregor D; Stosor V
    J Antimicrob Chemother; 2016 Sep; 71(9):2642-5. PubMed ID: 27330060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.